INmune Bio to Present RDEB Trial Data, Spotlighting Systemic Approach
Event summary
- INmune Bio will host a webinar on February 26, 2026, to present data from the MissionEB Phase III clinical trial for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB).
- The trial data will focus on systemic disease-modifying capabilities, specifically examining EBDASI scores, nutritional status, symptom reduction, and quality of life improvements.
- Dr. Anna Martinez, principal investigator of the MissionEB trial, and Professor Mark Lowdell, Chief Scientific Officer of INmune Bio, will present the findings.
- CORDStrom is a cell medicine comprised of pooled, allogeneic human umbilical cord-derived mesenchymal stromal cells (hucMSCs) designed as a systemic therapy, contrasting with current topical treatments.
The big picture
INmune Bio’s CORDStrom represents a shift towards systemic therapies for RDEB, a debilitating rare disease with limited treatment options. The Phase III data presentation is a pivotal moment for the company, as it seeks to validate its platform and potentially disrupt the current standard of care focused on topical wound management. Success hinges on demonstrating meaningful clinical improvements and navigating the complexities of manufacturing and regulatory approval for cell-based therapies.
What we're watching
- Clinical Efficacy
- The webinar’s data on EBDASI scores and symptom reduction will be critical in assessing CORDStrom’s true clinical impact, as these metrics are key drivers of regulatory approval and market adoption.
- Manufacturing Scalability
- Given CORDStrom’s reliance on pooled hucMSCs, the ability to consistently produce sufficient quantities of high-quality material for commercialization will be a significant operational hurdle to monitor.
- Market Adoption
- The success of CORDStrom will depend on physician and patient acceptance of a systemic approach to RDEB, which may require a shift in treatment paradigms and reimbursement models.
Related topics